Medication info
Olmedipin Tablet 5/20 mg (Amlodipine, Olmesartan)

Olmedipin Tablet 5/20 mg (Amlodipine, Olmesartan)

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
Myungin Pharmaceutical Co., Ltd.
Appearance
White round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201500863 · Approved 2015.02.17 · Insurance code 651904170

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not adequately controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should have their blood pressure and renal function closely monitored. This medicine must not be administered to patients with severe hepatic impairment. (See section 2. Patients in whom this medicine must not be administered, under Precautions for Use.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, monitor blood pressure closely and more frequently.
Child dose
Pediatric patients under 18 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Myungin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Amlodipine or Olmesartan Medoxomil is used as monotherapy when blood pressure is not adequately controlled in patients with essential hypertension. These medications effectively lower blood pressure and help prevent cardiovascular complications. By controlling blood pressure, they reduce the burden on the heart and blood vessels, thus improving health. This drug has proven therapeutic effects, and good results can be anticipated with consistent usage. It is recommended to use it safely, adjusting according to the patient's condition.

How to take

Adult dose

Take 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not adequately controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should have their blood pressure and renal function closely monitored. This medicine must not be administered to patients with severe hepatic impairment. (See section 2. Patients in whom this medicine must not be administered, under Precautions for Use.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, monitor blood pressure closely and more frequently.

Child dose

Pediatric patients under 18 years of age: Safety and efficacy have not been established.

Precautions

This drug can cause serious harm to the fetus and newborn, especially during pregnancy in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. It should not be used in patients with allergies to this drug's active ingredients or similar medications, pregnant or breastfeeding women, patients with severe liver disease or specific heart conditions, and patients undergoing kidney dialysis. Patients with dehydration or low sodium levels may experience hypotension, so careful monitoring is necessary at the start of treatment. In cases of rapid vascular dilation leading to hypotension, patients with severe aortic stenosis, obstructive coronary artery disease, or congestive heart failure should use this drug cautiously. Patients with impaired kidney function may experience worsening of kidney function when taking this drug, so caution is needed. Patients with reduced liver function may have delayed metabolism of this drug, so caution is recommended during use. During treatment, side effects such as dizziness, headache, hypotension, edema, indigestion, and skin rashes may occur; consult a doctor if any adverse symptoms arise. It is safer not to take this drug during pregnancy, and it should be discontinued immediately if pregnancy occurs while taking it. Breastfeeding women should be cautious since this drug can be passed through breast milk, which may cause adverse reactions in infants; therefore, either breastfeeding or taking this medication should be discontinued. This drug is not recommended for children under 18 years of age as its safety and efficacy have not been established for this demographic. Elderly patients should begin treatment with low doses, taking into account possible liver or kidney function decline. In case of overdose, severe hypotension and heart problems may occur, so the prescribed dosage must be strictly followed as per the doctor's instructions. This medication should be stored in a place away from direct sunlight and moisture, out of reach of children, and transferring it to another container should be avoided.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • sensory disturbances
  • sensory decline
  • syncope
Show 84 more
  • vertigo
  • palpitations
  • tachycardia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • indigestion
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • frequent urination
  • erectile dysfunction
  • peripheral edema
  • edema
  • dependent edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • herpes zoster
  • diplopia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • elevated serum creatinine
  • hair loss
  • itching
  • autoimmune hepatitis
  • hyperkalemia
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a sealed container. It is important to maintain a storage temperature between 1 to 30 degrees Celsius. By doing this, the effectiveness of the medication can be safely preserved.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.